South Korea
· Delayed Price · Currency is KRW Wonbiogen Statistics
Total Valuation
Wonbiogen has a market cap or net worth of KRW 40.01 billion. The enterprise value is 29.30 billion.
| Market Cap | 40.01B |
| Enterprise Value | 29.30B |
Important Dates
The next estimated earnings date is Friday, August 8, 2025.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Wonbiogen has 7.09 million shares outstanding. The number of shares has decreased by -6.02% in one year.
| Current Share Class | 7.09M |
| Shares Outstanding | 7.09M |
| Shares Change (YoY) | -6.02% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 32.42% |
| Owned by Institutions (%) | n/a |
| Float | 4.79M |
Valuation Ratios
The trailing PE ratio is 6.85.
| PE Ratio | 6.85 |
| Forward PE | n/a |
| PS Ratio | 1.27 |
| PB Ratio | 1.06 |
| P/TBV Ratio | 1.08 |
| P/FCF Ratio | 5.82 |
| P/OCF Ratio | 5.23 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.55, with an EV/FCF ratio of 4.26.
| EV / Earnings | 4.99 |
| EV / Sales | 0.93 |
| EV / EBITDA | 3.55 |
| EV / EBIT | 4.43 |
| EV / FCF | 4.26 |
Financial Position
The company has a current ratio of 5.15, with a Debt / Equity ratio of 0.02.
| Current Ratio | 5.15 |
| Quick Ratio | 3.85 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.11 |
| Debt / FCF | 0.13 |
| Interest Coverage | 123.17 |
Financial Efficiency
Return on equity (ROE) is 15.68% and return on invested capital (ROIC) is 10.47%.
| Return on Equity (ROE) | 15.68% |
| Return on Assets (ROA) | 9.48% |
| Return on Invested Capital (ROIC) | 10.47% |
| Return on Capital Employed (ROCE) | 17.05% |
| Revenue Per Employee | 416.10M |
| Profits Per Employee | 77.29M |
| Employee Count | 76 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 2.77 |
Taxes
In the past 12 months, Wonbiogen has paid 1.15 billion in taxes.
| Income Tax | 1.15B |
| Effective Tax Rate | 17.22% |
Stock Price Statistics
The stock price has increased by +268.35% in the last 52 weeks. The beta is 0.68, so Wonbiogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | +268.35% |
| 50-Day Moving Average | 2,293.94 |
| 200-Day Moving Average | 1,535.97 |
| Relative Strength Index (RSI) | 90.22 |
| Average Volume (20 Days) | 39,892 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Wonbiogen had revenue of KRW 31.62 billion and earned 5.87 billion in profits. Earnings per share was 823.29.
| Revenue | 31.62B |
| Gross Profit | 14.92B |
| Operating Income | 6.57B |
| Pretax Income | 6.70B |
| Net Income | 5.87B |
| EBITDA | 8.20B |
| EBIT | 6.57B |
| Earnings Per Share (EPS) | 823.29 |
Balance Sheet
The company has 11.68 billion in cash and 897.75 million in debt, giving a net cash position of 10.78 billion or 1,519.93 per share.
| Cash & Cash Equivalents | 11.68B |
| Total Debt | 897.75M |
| Net Cash | 10.78B |
| Net Cash Per Share | 1,519.93 |
| Equity (Book Value) | 37.81B |
| Book Value Per Share | 5,319.60 |
| Working Capital | 18.82B |
Cash Flow
In the last 12 months, operating cash flow was 7.65 billion and capital expenditures -780.43 million, giving a free cash flow of 6.87 billion.
| Operating Cash Flow | 7.65B |
| Capital Expenditures | -780.43M |
| Free Cash Flow | 6.87B |
| FCF Per Share | 968.52 |
Margins
Gross margin is 47.19%, with operating and profit margins of 20.77% and 18.57%.
| Gross Margin | 47.19% |
| Operating Margin | 20.77% |
| Pretax Margin | 21.20% |
| Profit Margin | 18.57% |
| EBITDA Margin | 25.94% |
| EBIT Margin | 20.77% |
| FCF Margin | 21.73% |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 1.77%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 1.77% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 12.07% |
| Buyback Yield | 6.02% |
| Shareholder Yield | 7.79% |
| Earnings Yield | 14.68% |
| FCF Yield | 17.17% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 7, 2025. It was a reverse split with a ratio of 0.2.
| Last Split Date | May 7, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Wonbiogen has an Altman Z-Score of 8.43 and a Piotroski F-Score of 7.
| Altman Z-Score | 8.43 |
| Piotroski F-Score | 7 |